University of Oulu

Rios, J. L., Sapède, D., Djouad, F., Rapp, A. E., Lang, A., Larkin, J., Ladel, C., & Mobasheri, A. (2022). Animal models of osteoarthritis part 1–preclinical small animal models: Challenges and opportunities for drug development. Current Protocols, 2, e596. doi: 10.1002/cpz1.596

Animal models of osteoarthritis part 1–preclinical small animal models: challenges and opportunities for drug development

Saved in:
Author: Rios, Jaqueline Lourdes1; Sapède, Dora2; Djouad, Farida2;
Organizations: 1Department of Orthopedics, University Medical Center Utrecht, Utrecht, The Netherlands
2IRMB, Université de Montpellier, INSERM, Montpellier, France
3Dr. Rolf M. Schwiete Research Unit for Osteoarthritis, Department of Orthopaedics (Friedrichsheim), University Hospital Frankfurt, Frankfurt am Main, Germany
4McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
5Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
6SynOA Therapeutics, Philadelphia, Pennsylvania
7CHL4 Special Consultancy, Darmstadt, Germany
8Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
9Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania
10Departments of Orthopaedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
11Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
12World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.9 MB)
Persistent link:
Language: English
Published: John Wiley & Sons, 2022
Publish Date: 2022-11-18


Osteoarthritis (OA) is the most common form of arthritis and a major source of pain and disability in the adult population. There is a significant unmet medical need for the development of effective pharmacological therapies for the treatment of OA. In addition to spontaneously occurring animal models of OA, many experimental animal models have been developed to provide insights into mechanisms of pathogenesis and progression. Many of these animal models are also being used in the drug development pipeline. Here, we provide an overview of commonly used and emerging preclinical small animal models of OA and highlight the strengths and limitations of small animal models in the context of translational drug development. There is limited information in the published literature regarding the technical reliability of these small animal models and their ability to accurately predict clinical drug development outcomes. The cost and complexity of the available models however is an important consideration for pharmaceutical companies, biotechnology startups, and contract research organizations wishing to incorporate preclinical models in target validation, discovery, and development pipelines. Further considerations relevant to industry include timelines, methods of induction, the key issue of reproducibility, and appropriate outcome measures needed to objectively assess outcomes of experimental therapeutics. Preclinical small animal models are indispensable tools that will shine some light on the pathogenesis of OA and its molecular endotypes in the context of drug development. This paper will focus on small animal models used in preclinical OA research. © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.

see all

Series: Current protocols
ISSN: 2691-1299
ISSN-E: 2691-1299
ISSN-L: 2691-1299
Volume: 2
Issue: 11
Article number: e596
DOI: 10.1002/cpz1.596
Type of Publication: A2 Review article in a scientific journal
Field of Science: 3111 Biomedicine
Funding: JL, CL, and AM wish to acknowledge financial support from the Innovative Medicines Initiative Joint Undertaking under grant agreement 115770, the resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution. See and AM wishes to acknowledge financial support from the European Structural and Social Funds through the Research Council of Lithuania (Lietuvos Mokslo Taryba) according to the Programme Attracting Foreign Researchers for Research Implementation, grant no. 01.2.2-LMT-K-718-02-0022. AM also wishes to acknowledge the financial support of the Academy of Finland through a research grant starting September 2022 and the Profi6 336449 grant awarded to the University of Oulu. JLR wishes to acknowledge financial support from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska Curie grant agreement 955335 (CARTHAGO) and 956477 (PIANO). DS wishes to acknowledge financial support from the Agence Nationale pour la Recherche (ANR-18-CE18-0010).
Copyright information: © 2022 The Authors. Current Protocols published by Wiley Periodicals LLC.This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivsLicense, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.